FDA Warns DTC Genetic Test Firms
This article was originally published in The Tan Sheet
Executive Summary
The warning letters are the first FDA sent since it carved out a de novo risk category
for DTC carrier screening tests, clearing the path for 23andMe Inc. to relaunch its Personal Genome Service in October.
You may also be interested in...
Size Of 23andMe Data Breach Jumps To Nearly 7M
Numbers for genetic testing company’s October data breach much larger than previously reported; company might be trying to shield itself from class action complaints.
After At-Home Diagnostics Got Boost From COVID, FTC Shows False Claims Didn’t End With Pandemic
FTC and California Attorney General offer CRI Genetics LLC as exhibit A for making good on promised deliverables for DNA-based ancestry and information reports.
Personal Genome Service For Carrier Screening Emerges From 23andMe Work With FDA
Two years of conversations with FDA lead 23andMe back to the health care market with the launch of its Personal Genome Service, focused on carrier screening tests. The firm says its close engagement with FDA improved its customer communication and quality control.